Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: A supramolecular nanovehicle toward systematic, targeted cancer and tumor therapy
Ruizheng
Liang†
a,
Shusen
You†
a,
Lina
Ma
b,
Chunyang
Li
a,
Rui
Tian
a,
Min
Wei
*a,
Dan
Yan
*b,
Meizhen
Yin
*a,
Wantai
Yang
a,
David G.
Evans
a and
Xue
Duan
a
aState Key Laboratory of Chemical Resource Engineering, Beijing Laboratory of Biomedical Materials, Beijing University of Chemical Technology, Beijing 100029, P. R. China. E-mail: weimin@mail.buct.edu.cn; yinmz@mail.buct.edu.cn; Fax: +86-10-64425385; Tel: +86-10-64412131
bBeijing Shijitan Hospital, Capital Medical University, Beijing 100038, P. R. China. E-mail: yd277@126.com
First published on 6th August 2025
Abstract
Correction for ‘A supramolecular nanovehicle toward systematic, targeted cancer and tumor therapy’ by Ruizheng Liang et al., Chem. Sci., 2015, 6, 5511–5518, DOI: https://doi.org/10.1039/C5SC00994D.
It has come to the authors' attention that some errors have been found in Fig. 3. The two fluorescence staining images in Fig. 3C were unexpectedly misused due to carelessness when editing the figure. The corrected Fig. 3 is shown below. This correction does not affect the results and conclusions of the study.
 | ||
| Fig. 3 The antitumor performance of (A) DOX/SNV, DOX, ZnPc-DOX/PVP-Br, ZnPc-DOX/SNV, (B) ZnPc, ZnPc/PVP-Br, ZnPc/SNV, ZnPc-DOX/SNV, with a concentration in the range 0–10 μg mL−1 after 24 h incubation and 0.5 h irradiation. Fluorescence microscopy and merged images of the HepG2 cells treated with various samples and irradiation (5 μg mL−1 and 24 h incubation): (C) ZnPc, (D) ZnPc (5.3%)/PVP-Br, (E) ZnPc (5.3%)/SNV, (F) blank, (G) DOX, (H) DOX/SNV, (I) ZnPc-DOX/PVP-Br, (J) ZnPc-DOX/SNV. | ||
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
Footnote |
| † These authors equally contributed to this work. |
| This journal is © The Royal Society of Chemistry 2025 |